Key Drivers
- Very high gross-margin
- Large cash buffer
- Negative equity/leverage
AIAI Summary
Ascendis' transition to a commercial-stage specialty pharma with high product gross margins and early positive operating cash flow reframes valuation toward execution—monitor sequential revenue growth, payer approval rates for TransCon CNP, and near‑term debt/refinancing milestones because commercialization execution or reimbursement shortfalls (and leverage pressure) will determine upside versus downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross-margin
- •Large cash buffer
- •Negative equity/leverage
ASND has strong gross margins and ample cash but faces persistent operating losses, heavy R&D-driven cash burn, negative equity with very high leverage, and an outsized valuation relative to revenue.
Price Behavior
Key Price Behavior Insights:
- •Mild decline
- •Clear resistance
- •Nearby support
Over the last month ASND has mildly declined ~1–2% to $221.88 from $225 after a short-lived peak near $242 that established clear resistance and prompted a pullback toward a $222–$224 support band, whose decisive break would increase downside risk.
Intraperiod peak near $242 followed by a swift pullback to $221.88 within the month
Sentiment & News
Key News Insights:
- •Institutional flows
- •FDA approval
- •Legal headwinds
Ascendis's FDA approval of YUVIWEL, supportive long‑term and Turner syndrome data, and planned U.S. launch drove renewed institutional interest despite BioMarin legal challenges and modest near‑term sales forecasts.
Approval and strong data materially improve long‑term commercial upside, but near‑term share gains may be muted by legal and competitive risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings